Thomas Strack

Thomas Strack has a long history of experience in the pharmaceutical industry. Thomas began in 1993 at Eli Lilly & Company as a Senior Scientist Regulatory Affairs. In 2000, they moved to Pfizer Pharmaceuticals as a Senior Director Clinical Sciences. In 2009, they became a Vice President, Therapeutic Area Head Diabetes and Metabolic Diseases at Takeda Pharmaceuticals. In 2012, they were appointed Vice President, Head R/D at Asubio Pharmaceuticals US (wholly owned subsidiary of Daiichi-Sankyo Inc.). From 2015 to 2018, they were at Progenics Pharmaceuticals, Inc. as Vice President Clinical Development. In 2018, they became a Medical Affairs Consultant at Omeros Corporation. Most recently, in 2019, they joined Molecular Templates as Senior Vice President Clinical Development and Medical Affairs and in 2022 they were appointed Chief Medical Officer at Faeth Therapeutics.

Thomas Strack obtained their MD from Johannes Gutenberg University Mainz in 1978 to 1984. From 1986 to 1987, they completed a Postdoctoral Research Fellowship at the Hospital for Sick Children at the University of Toronto. From 1983 to 1985, they completed a Doctorate in Biomedical/Medical Engineering at Johannes Gutenberg University Mainz. In 1992, they obtained Board Certification in Internal Medicine from Johannes Gutenberg University Mainz. In 1995, they obtained Board Certification in Endocrinology from Johannes Gutenberg University Mainz. In 2021, they obtained PMQ certification from SHRM. Additionally, they hold Internal Medicine & Endocrinology certification from the German Medical Association.